INTRODUCTION {#s1}
============

Breast cancer remains one of the most devastating diseases worldwide. Traditionally, estrogen receptor (ER), progesterone receptor (PR) and Her2 have been used to classify breast cancer into three subtypes: positive for hormonal receptors (ER+), Her2+, and triple negative (TNBC) without these receptors. While ER+ tumors are treated with selective ER modulators or aromatase inhibitors and Her2+ tumors are treated with antibodies against this receptor \[[@R1]\], TNBC tumors do not have a specific treatment, prompting the search for innovative approaches. A genome-wide association study (GWAS) revealed the tumor necrosis factor superfamily member 13B (*TNFSF13B*) gene, suggesting new target-specific therapies \[[@R2]\]. Translation of these transcriptome results to clinical practice is underway. The clinical significance of a breast-cancer-associated, 70-gene signature panel (a.k.a., MammaPrint^®^ signature) was first reported as a clinical tool to help refine prognosis in the NEJM fourteen years ago \[[@R2]\], as implemented by Agendia BV, Amsterdam, The Netherlands for scale-up clinical trials. Initially, van 't Veer and colleagues screened a total of 25,000 genes of using microarray technology for supervised clustering on mRNA expression of 70 genes and van 't Veer *et al*. validated for either a low or high risk of patients. The 70-genes assay was adopted in the US for clinical practice since van 't Veer moved to University of California, San Francisco. Based on the 70-gene MammaPrint^®^ signature, the same group reported a follow-up *NEJM* article, showing that "no chemotherapy led to a 5-year rate of survival without distant metastasis that was 1.5% lower than the rate with chemotherapy", with 1550 patients (23.2%) at high clinical risk and low genomic risk for recurrence, out of a randomized Phase 3 study with 6693 enrolled early-stage breast cancer patients \[[@R3]\]. This suggests that approximately 46% of women at high clinical risk may not need chemotherapy. Monitoring the MammaPrint^®^ 70-gene signature can guide the treatment. However, these genes were selected empirically from breast cancer cases through time. It is not clear why these genes have predictive power and whether such a panel can be applied to other types of cancers.

Here, we report a new algorithm to cluster genes that share the same cell cycle phase (i.e., G~0~, G~1~, S, or G~2~) based on a spectrum of single-cell transcriptomes from a cell-cycle model system. This algorithm allows cells to be sorted into subpopulations of sharing the same cell-cycle phases. We inferred a possible mechanism by which predictive power of MammaPrint^®^ signature predicts its clinical outcomes for breast cancer.

RESULTS {#s2}
=======

We defined phase-specific, cell-cycle-dependent single-cell transcriptomes using the model system - Fucci cells, which have fluorescent cell-cycle phase-specific indicators. We obtained single-cell transcriptomes from these Fucci cells with our microfluidic platform with nanoliter reactors \[[@R5]\]. Combining these two technologies allowed for the characterization of a cell cycle phase-specific map using a similarity matrix (algorithm) based on known cell cycle genes (GO:0022402). We used this algorithm to create a novel cell cycle map of known cell cycle genes in the corresponding sequential order (Figure [1](#F1){ref-type="fig"}). As expected, known cell cycle genes had expression perturbation profiles that agreed with previously reported studies of physical cell lysates. In addition to known cell cycle genes, genes indicated by the Self-Organizing Map (SOM) analysis were also plotted onto the cell cycle map to identify novel candidate cell cycle genes, termed cell cycle index.

![Sequential perturbations of cell-cycle-specific genes in a single-cell model system\
After organizing single-cell transcriptomes by similarity into a sequencing order, expression levels of various cell-cycle-specific genes were plotted to visualize the sequential perturbation of individual genes during the cell cycle. Cell cycle phases were defined and colored based on the cell cycle molecular map. As expected, G0/G1-specific genes had higher expression levels in the G0/G1 phase (**A**) and G2/M-specific genes had high expression levels in the G2/M phase (**B**). G2/M-specific genes had high expression levels in the G2/M phase and the early G0/G1 phase (**C**). Note: the numbers along the outside circle (\#1 -- 29) represent the cell cycle phase: \#1- \#15 for G1-phase; \#16-\#22, S-phase; \#23-\#29, G2/M-phase. The number on the vertical scale radiating from the center represents the level of gene expression with the center representing 0, the lowest, scaling up to the outer circle, the highest.](oncotarget-09-33290-g001){#F1}

We applied this algorithm to assess the cell cycle activity of the MammaPrint^®^ 70-gene signature \[[@R4]\] to create a cell-cycle index for cell-cycle-phase-specific mapping as generated from single-cell transcriptomes. In addition to the previously reported 15 cell cycle-related genes \[[@R5], [@R6]\], our strategy revealed 23 additional cell cycle-associated genes among the 70 MammaPrint^®^ genes. Among the 23 newly identified cell cycle-related genes, we identified 15 genes regulating G1 phase (Figure [2B](#F2){ref-type="fig"}), 5 genes regulating S-phase (Figure [2C](#F2){ref-type="fig"}), and 3 genes regulating G2 phase (Figure [2A](#F2){ref-type="fig"}). More importantly, these cell cycle specific genes are associated with clinical outcomes, as judged with current database of breast cancer patients' consequences in multiple reports and clinical trials, including cancer recurrence (Table [1](#T1){ref-type="table"}), cancer pathological stage (Table [2](#T2){ref-type="table"}), and primary versus metastatic disease (Table [3](#T3){ref-type="table"}).

![Perturbation of MammaPrint^®^ genes during cell cycle suggests that many MammaPrint^®^ genes are cell cycle regulators\
With microfluidic devices, transcriptomes of individual cells were arranged by similarity to construct a cell cycle map with 29 single-cells with each single-cell represented a specific stage of the cell cycle. The distance between cells represent their similarity with neighboring cells. The map reveals the stepwise perturbations of all genes during the cell cycle, such as G1-phase, S-phase, and G2-phase. The mRNA perturbation of majority of MammaPrint^®^ genes was plotted and presented by expression levels. (**A**) Highly expression MammaPrint^®^ gene; (**B**) medium expression MammaPrint^®^ genes and (**C**) low expression MammaPrint^®^ genes. Genes at all level of expression showed cell-cycle dependent perturbation patterns. These results suggest that majority of MammaPrint^®^ genes are cell cycle regulators and MammaPrint^®^ gene panel is a cell cycle index panel.](oncotarget-09-33290-g002){#F2}

###### Breast cancer recurrence governed by cell cycle regulated genes^\*^

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene name   Incidence of patient\'s recurrence                  Expression median   Fold change   *P*-value   Gene rank          Reference
  ----------- --------------------------------------------------- ------------------- ------------- ----------- ------------------ -------------------------------
  CCNE2       No Recurrence at 3 Years (*N* = 6)                                      −1.381        0.03        467 (in top 3%)    Esserman *et al*., 2012

              Recurrence at 3 Years (*N* = 3)                                         −0.654                                       Esserman *et al*., 2012

  CENPA       1\. No Recurrence at 3 Years (*N* = 10)             --0.44                            1.76E-04    20 (in top 1%)     Desmedt *et al*., 2007

              2\. Recurrence at 3 Years (*N* = 3)                 1.197                                                            

              1\. No Recurrence at 5 Years (*N* = 9)              --0.707                           2.29E-04    24 (in top 1%)     Desmedt *et al*., 2007

              2\. Recurrence at 5 Years (*N* = 3)                 1.197                                                            

              1\. Alive at 3 Years (*N* = 77)                     --134                             0.002       187 (in top 1%)    Esserman *et al*., 2012

              2\. Dead at 3 Years (*N* = 15)                      --0.355                                                          

              1\. Alive at 5 Years (*N* = 21)                     --1.807                           2.12E-04    26 (in top 1%)     Esserman *et al*., 2012

              2\. Dead at 5 Years (*N* = 20)                      --566                                                            

              1\. No Recurrence at 3 Years (*N* = 78)             1.373                             0.01        380 (in top 2%)    Loi *et al*., 2007

              2\. Recurrence at 3 Years (*N* = 8)                 2.246                                                            

              1\. No Recurrence at 5 Years (*N* = 66)             --0.062                           0.007       471 (in top 3%)    Loi *et al*., 2008

              2\. Recurrence at 5 Years (*N* = 10)                0.604                                                            

  LIN9        No Recurrence at 3 Years (*N* = 69)                 0.418                             0.009       589 (in top 4%)    Esserman *et al*., 2012

              Recurrence at 3 Years (*N* = 24)                    0.722                                                            

              1\. No Recurrence at 5 Years (*N* = 8)              0.594                             0.011       924 (in top 5%)    Finak *et al*., 2008

              2\. Recurrence at 5 Years (*N* = 11)                1.149                                                            

  RUNDC1                                                          1.442                             0.151       5579               TCGA Breast (database)

                                                                  --1.059                           0.52        8666               Radvanyi *et al*., 2005

                                                                  --1.061                           0.592       13627              Bittner (database)

  BRCA2       Recurrence at 3 years (*N* = 4)                     0.596                             0.014       516 top 3%         Loi *et al*., 2008

              No Recurrence at 3 years (*N* = 72)                 --0.076                                                          Loi *et al*., 2008

              Recurrence or metastasis at 5 years (*N* = 6)       0.639                             4.83E-04    87 top 1%          Loi *et al*., 2008

              No Recurrence or metastasis at 5 years (*N* = 69)   --0.09                                                           Loi *et al*., 2008

              Recurrence at 5 Years (*N* = 10)                    --0.257                           0.043       861 top 6%         Ma *et al*., 2003

              No Recurrence at 5 Years (*N* = 22)                 --1.602                                                          Ma *et al*., 2003

              Recurrence at 3 Years (*N* = 3)                     --1.427                           0.038       958 top 8%         Desmedt *et al*., 2007

              No Recurrence at 3 Years (*N* = 10)                 --2.141                                                          Desmedt *et al*., 2007

  CCNB1       Recurrence or metastasis at 3 years (*N* = 8)       3.124                             0.002       103 top 1%         Loi *et al*., 2007

              No Recurrence or metastasis at 3 years (*N* = 78)   2.465                                                            Loi *et al*., 2007

              Recurrence or metastasis at 5 years (*N* = 14)      3.124                             0.023       1306 top 7%        Loi *et al*., 2007

              No Recurrence or metastasis at 5 years (*N* = 68)   2.465                                                            Loi *et al*., 2007

              No Recurrence at 3 Years (*N* = 71)                 --0.04                            0.018       487 (in top 3%)    Loi *et al*., 2008

              Recurrence at 3 Years (*N* = 5)                     0.853                                                            Loi *et al*., 2008

              No Recurrence at 3 Years (*N* = 10)                 1.338                             0.046       1130 (in top 9%)   Desmedt *et al*., 2007

              Recurrence at 3 Years (*N* = 3)                     2.709                                                            Desmedt *et al*., 2008

  CDC25A      No Recurrence at 1 Year (*N* = 269)                 --1.985                           0.002       312 (in top 3%)    Esserman *et al*., 2012

              Recurrence at 1 Year (*N* = 16)                     --0.749                                                          Esserman *et al*., 2012

              No Recurrence at 3 Years (*N* = 217)                --2.08                            6.83E-04    532 (in top 5%)    Esserman *et al*., 2012

              Recurrence at 3 Years (*N* = 68)                    --1.078                                                          Esserman *et al*., 2012

              1\. No Recurrence at 3 Years (*N* = 10)             --2.893                           0.002       94 (in top 1%)     Esserman *et al*., 2012

              2\. Recurrence at 3 Years (*N* = 3)                 --0.037                                                          Esserman *et al*., 2012

  CDC25C      No Recurrence at 3 Years (*N* = 10)                 --0.706                           0.002       79 (in top 1%)     Loi *et al*., 2007

              Recurrence at 3 Years (*N* = 3)                     --0.12                                                           Loi *et al*., 2007

              No Recurrence at 5 Years (*N* = 9)                  --0.879                           0.002       82 (in top 1%)     Desmedt *et al*., 2007

              Recurrence at 5 Years (*N* = 3)                     --0.12                                                           Desmedt *et al*., 2007

              No Recurrence at 3 Years (*N* = 78)                 0.193                             0.006       245 (in top 2%)    Loi *et al*., 2007

              Recurrence at 3 Years (*N* = 8)                     0.893                                                            Loi *et al*., 2008

              No Recurrence at 5 Years (*N* = 68)                 0.138                             0.002       118 (in top 1%)    Loi *et al*., 2009

              Recurrence at 5 Years (*N* = 14)                    0.893                                                            Loi *et al*., 2010

              No Recurrence at 3 Years (*N* = 6)                  --1.563                           0.038       917 (in top 5%)    Esserman *et al*., 2012

              Recurrence at 3 Years (*N* = 5)                     --0.795                                                          Esserman *et al*., 2013

  CDKN2D      No Recurrence at 5 Years (*N* = 68)                 0.405                             0.009       584 (in top 3%)    Loi *et al*., 2007

              Recurrence at 5 Years (*N* = 14)                    0.6                                                              

              No Recurrence at 3 Years (*N* = 229)                --0.051                           0.001       491 (in top 4%)    van de Vijver *et al*., 2002\
                                                                                                                                   MammaPrint®

              Recurrence at 3 Years (*N* = 63)                    0.01                                                             MammaPrint 70-gene list

              No Recurrence at 5 Years (*N* = 68)                 --0.059                           9.53E-04    489 (in top 4%)    van de Vijver *et al*., 2002\
                                                                                                                                   MammaPrint®

              Recurrence at 5 Years (*N* = 14)                    0.006                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

^\*^Novel phase-related genes in red on A column.

###### Pathological stages of breast cancer governed by biomarkers expression^\*^

  Gene name   Stage and number of patients                                        Fold change   *P*-value   Gene rank           Reference
  ----------- ------------------------------------------------------------------- ------------- ----------- ------------------- ---------------------------
  CCNE2       Grade 3 (10) vs Grade 2 (20)                                        2.073         0.002       149 (in top 1%)     MA XJ *et al*., 2004
  CENPA       TP53 Mutation (84) vs TP53 Wild Type (557)                          1.679         1.82E-16    1 (in top 1%)       Curtis *et al*., 2012
              ERBB2/ER/PR Negative (211) vs another Biomarker Status (1,340)      2.135         7.02E-57    25 (in top 1%)      Curtis *et al*., 2012
              Stage II (4) vs Stage I (3)                                         1.706         0.009       139 (in top 1%)     Curtis *et al*., 2012
              ERBB2/ER/PR Negative (39) vs Another Biomarker Status (129)         2.402         4.33E-08    94 (in top 1%)      Bittner *et al*., 2005
              M1+ (5) vs M0 (176)                                                 2.327         1.00E-02    996 (in top 6%)     Bittner *et al*., 2005
              N1+ (12) vsN0 (7)                                                   4.343         9.95E-05    12 (in top 1%)      Lu *et al*., 2008
              Grade 3 (4) vs Grade 2 (3)                                          2.221         8.00E-03    188 (in top 2%)     Desmedt *et al*., 2007
              TP53 Mutation (58) vsTP53 Wild Type (189)                           1.67          3.94E-13    41 (in top 1%)      Ivshina *et al*., 2006
              TP53 Mutation (58) vsTP53 Wild Type (189)                           1.502         5.17E-04    521 (in top 3%)     Gluck *et al*., 2012
              ERBB2/ER/PR Negative (39) vs other Biomarker Status (129)           2.086         5.80E-04    751 (in top 4%)     Richardson *et al*., 2006
              ERBB2/ER/PR Negative (39) vs other Biomarker Status (129)           3.625         5.90E-04    178 (in top 2%)     Zhao H *et al*., 2004
  LIN9        N1+ (12) vs N0 (7)                                                  1.658         7.86E-04    94 (in top 1%)      Lu *et al*., 2008
              ERBB2/ER/PR Negative (39) vs Another Biomarker Status (129)         1.627         1.00E-06    261 (in top 2%)     Bittner *et al*., 2005
              ERBB2/ER/PR Negative (18) vs Another Biomarker Status (19)          1.732         2.96E-04    575 (in top 3%)     Richardson *et al*., 2006
  RUNDC1      Grade 3 (3) vs Grade 2 (24) vs Grade 1 (13)                                       0.038       1023 (in top 6%)    Curtis *et al*., 2012
              Grade 3 (17) vs Grade 2 (3)                                         1.183         0.044       3511 (in top 19%)   Nik-Zainal *et al*., 2012
  BRCA2       Grade 3 (10) vs Grade 2 (20)                                        2.693         4.13E-06    4 (in top 1%)       MA XJ *et al*., 2004
              Dead at 1 Year (7) vs Alive at 1 Year (47)                          1.962         3.10E-05    4 (in top 1%)       Sorlie *et al*, 2001
              Dead at 1 Year (12) vs Alive at 1 Year (69)                         1.594         0.002       42 (in top 1%)      Sorlie *et al*, 2003
              Grade 3 (3) vs Grade 2 (7)                                          5.117         0.009       752 (in top 6%)     Desmedt *et al*., 2007
  CCNB1       ERBB2/ER/PR Negative (39) versus other (129)                        1.712         4.28E-05    811 top 5%          Bittner *et al*., 2005
              M0 (176) vs M1+ (5)                                                 1.634         0.018       1461 top 8%         
              Grade 3 (10) vs Grade 2 (20)                                        1.782         0.006       299 top2 %          MA XJ *et al*., 2004
              N1+ (12) vs N0 (7)                                                  3.198         3.56E-04    47 top 1%           Lu *et al*., 2008
  CDC25A      Grade 3 (3) vs Grade 2 (7)                                          8.625         9.48E-04    175 (in top 2%)     Desmedt *et al*., 2007
              ERBB2/ER/PR Negative (39) vs positive                               2.324         4.74E-05    838 (in top 5%)     Bittner *et al*., 2005
                                                                                  2.452         3.04E-04    40 (in top 1%)      Ma XJ *et al*., 2004
  CDC25C      Grade 3 (3) vs Grade 2 (7)                                          4.042         0.001       221 (in top 2%)     Desmedt *et al*., 2007
              Bloom-Richardson Grade 2 (8) vs Bloom-Richardson Grade 1 (5)        2.228         0.008       1130 (in top 6%)    Lu *et al*., 2008
              Elston Grade 3 (16) vs Elston Grade 2 (37) vs Elston Grade 1 (17)                 1.04E-07    27 (in top 1%)      Loi *et al*., 2007
  CDKN2D      M1+ (5) vs M0 (176)                                                 1.921         7.76E-04    227 (in top 2%)     Bittner *et al*., 2005
              N1+ (16) vs N0 (14)                                                 1.99          0.032       1455 (in top 8%)    Bittner *et al*., 2005
              Grade 3 (10) vs Grade 2 (20)                                        1.533         0.009       383 (in top 3%)     MA XJ *et al*., 2004
              M1+ (8) vsM1+ (8)                                                   1.503         0.012       921 (in top 5%)     Kao KJ *et al*., 2011

^\*^Novel phase-related genes in red on A column.

###### Breast cancer biomarkers *In Silico* analysis: Metastasis vs primary^\*^

  Gene name   Metastasis vs primary                 Fold change   *P*-value   Gene rank       Reference
  ----------- ------------------------------------- ------------- ----------- --------------- ------------------------------
  CCNE2       Metastasis vs primary                 1.681         0.058       2249            Bittner Breast database 2005
              Metastasis vs primary                 1.214         0.307       3190            Weigelt *et al*., 2003
              Metastasis vs primary                 --1.423       0.786       12226           Radvanyi *et al*., 2005
              Metastasis vs primary                 --1.119       0.578       13819           TCGA 2005 database
  CENPA       Metastasis vs primary                 2.464         0.032       168             Weigelt *et al*., 2003
              Metastasis vs primary                 1.057         0.131       2895            Haverty Breast
              Metastasis vs primary                 1.521         0.096       3298            Bittner Breast database 2005
              Metastasis vs primary                 1.828         0.155       4115            Radvanyi *et al*.., 2005
  LIN9        Metastasis vs primary                 1.445         0.174       5203            Bittner Breast database 2005
              Metastasis vs primary                 --1.085       0.581       9471            Radvanyi *et al*., 2005
              Metastasis vs primary                 --1.176       0.825       17493           TCGA 2005 database
  RUNDC1      Metastasis vs primary                 1.442         0.151       5579            TCGA 2005 database
              Metastasis vs primary                 --1.059       0.52        8666            Radvanyi *et al*.., 2005
              Metastasis vs primary                 --1.061       0.592       13627           Bittner Breast database 2005
  BRCA2       Metastasis vs primary                 --1.036       0.55        3551            Sorlie *et al*, 2003
              Metastasis vs primary                 --1.034       0.61        6852            Weigelt *et al*., 2003
              Metastasis vs primary                 1.09          0.326       8552            Bittner Breast database 2005
              Metastasis vs primary                 --1.531       0.851       13239           Radvanyi *et al*., 2005
              Metastasis vs primary                 --1.287       0.699       15588           TCGA 2005 database
  CCNB1       Metastasis (9) versus primary (327)   1.506         0.05        2037 top 11%    Bittney database 2005
              Metastasis (5) versus primary (103)   --1.212       0.748       4538 top 74%    Sorlie *et al*., 2001
              Metastasis (6) versus primary (4)     --1.313       0.807       8893 top 87%    Weigelt *et al*., 2003
              Metastasis (7) versus primary (47)    --1.397       0.703       11075 top 67%   Radvanyi *et al*.., 2005
              Metastasis (3) versus primary (529)   --1.133       0.687       15399 top 76%   TCGA 2005 database
  CDC25A      Metastasis vs primary                 1.673         0.014       828             Bittner Breast database 2005
              Metastasis vs primary                 --1.016       0.518       3417            Sorlie *et al*, 2003
              Metastasis vs primary                 1.098         0.357       3809            Weigelt *et al*., 2003
              Metastasis vs primary                 1.488         0.149       4018            Radvanyi *et al*.., 2005
              Metastasis vs primary                 --1.407       0.76        16431           TCGA 2005 database
  CDC25C      Metastasis vs primary                 2.248         0.017       932             Bittner Breast database 2005
              Metastasis vs primary                 1.101         0.1         1140            TCGA Breast 2 database
              Metastasis vs primary                 1.618         0.082       593             Weigelt *et al*., 2003
  CDKN2D      Metastasis vs primary                 1.415         0.01        224             Sorlie *et al*, 2003
              Metastasis vs primary                 1.464         0.535       3559            Bittner Breast database 2005
              Metastasis vs primary                 --1.02                    6008            Weigelt *et al*., 2003

^\*^Novel phase-related genes in red on A column.

Specifically, nine genes of the 70 MammaPrint^®^ genes are regulated in a cell cycle specific pattern at cancer recurrence (Table [1](#T1){ref-type="table"}), including CCNE2, CENPA, LIN9, RUNDC1, BRCA2, CCNB1, CDC25A, CDC25C, and CDKN2D. Four of these nine genes, CCNE2, CENPA, LIN9, RUNDC1, are newly defined as phase-related genes of cell cycle, which can be used as prognostic biomarkers for either 3- or 5-year survival with *p*-Value \< 0.05. In particular, CCNB1 in the cohort of "Recurrence or metastasis at 3 years (*N* = 8 patients)" showed a 3.124-fold change (*p* = 0.002), in the cohort of "No Recurrence or metastasis" at 3 years (*N* = 78 patients)" had a 2.465-fold change, in the cohort of "Recurrence or metastasis at 5 years (*N* = 14 patients)" had a 3.124-fold change (*p* = 0.023), and in the cohort of "No Recurrence or metastasis at 5 years (*N* = 68 patients) had a 2.465-fold change (Table [1](#T1){ref-type="table"}). In Table [3](#T3){ref-type="table"}, CENPA *in Silico* analysis of breast cancer biomarkers for metastasis vs. primary showed a 2.46-fold change (*p*-Value = 0.031, while CDC25C, a 2.24-fold change, *p* = 0.017. In Table [2](#T2){ref-type="table"}, biomarker-governed pathological stages consisted of these nine genes, in particular, CCNE2 showed a 2.073-fold change with *p* = 0.002; CENPA, associated ERBB2/ER/PR negative (211 patients) vs. other biomarker status (1,340 patients), a 2.402-fold change, *p* = 4.33E-08, and another cohort, CENPA associated with ERBB2/ER/PR negative (39 patients) vs. other biomarker status (129 patients), a 3.625-fold change, with *p* = 5.90E-04. In a small cohort, BRCA2-expression associated-Grade 3 (3 patients) vs. -Grade 2 (7 patients) showed a 5.117-fold change (*p* = 0.009), while CDC25A of Grade 3 (3 patients) vs. Grade 2 (7 patients) showed a 8.625-fold change (*p* = 9.48E-04) and CDC25A of ERBB2/ER/PR negative (39 patients) vs. positive had a 2.324-fold change with *p* = 4.74E-05. CDC25C in Grade 3 (3 patients) vs Grade 2 (7 patients) showed a 4.042-fold change (*p* = 0.001) while in the cohort of Bloom-Richardson Grade 2 (8 patients) vs. of Bloom-Richardson Grade 1 (5 patients), CDC25C had a 2.228-fold change with *p* = 0.008 (Table [2](#T2){ref-type="table"}). In summary, 38 (more than half, 54%) of the 70 MammaPrint^®^ genes are involved in cell cycle control; nine of which are associated with breast cancer patients.

DISCUSSION {#s3}
==========

Current commercially available assays include the MammaPrint^®^, OncotypeDX (the 21-gene Recurrence Score, with reverse transcriptase PCR (RT-PCR), PAM50/Prosigna (on the expression of 46 genes using quantitative PCR (qPCR), by NanoString Technologies, Seattle, WA), Endopredict (use the expression of 8 cancer-related and 3 reference genes determined with RT-PCR, by Myriad Genetics Inc, Salt Lake City, UT), of which four criteria is considered: "assay development and methodology, clinical validation, clinical utility and economic value" \[[@R7]\]. Although level IA clinical trial results show MammaPrint^®^ and OncotypeDX for prognostic information, clinical utility studies show a higher reduction in chemotherapy was achieved only by OncotypeDX. The inconsistency may be derived from inter-tumor and intra-tumor heterogeneity as these results were based on assays on bulky tumors. We have recently shown that a cancer relapse signaling pathway can be detected only in a single-cell transcriptome, not in a bulky tumor analysis, as bulky tumor transcriptomic analyses obscure the low signal of certain biomarkers \[[@R8]\]. We rationalized that single-cell transcriptomic analysis can enhance signal-to-noise ratio over bulky tumor transcriptomic analysis. Here, we discovered that a total of 38 genes (23 of them were revealed within the present work) measured with the MammaPrint^®^ assay are cell cycle regulated. We conclude that the MammaPrint^®^ assay would average out perturbations in gene expression when applied to a mixture of cells and thus remain undetected when using bulky tumors. We further illustrate that the advantage of our finding would make it possible (1) to attack the respective gene products using a combination therapy and (2) to deliver the right drugs to cells of the respective cell cycle stage.

More specifically, the results of these single-cell transcriptomes provide details relating to define perturbation of critical genes during the cell cycle. Such concentrating on cell cycle related genes reveals a possible mechanism for the greatest prognostic power of MammaPrint^®^. Our results, which have identified an additional 23 cell cycle-related genes, bring the total number of predicative genes to 38, thereby significantly improving the clinical value of the MammaPrint^®^ panel. We propose that these results can be applied to focus potential strategies to create more efficacious, targeted combinations of drugs, specifically addressing the appropriate cells in the correct cell cycle stage \[[@R9], [@R10]\]. We suggest this cell cycle stage index (i.e., mapping out a spectrum of a specific phase of the cell cycle for a particular single cell) can be applied in cancer treatment (Figure [3](#F3){ref-type="fig"}) by monitoring subclonal growth through determination of switchboard signals (i.e., cytokines and chemokines) which may transform cells from dormancy to dominating subclones \[[@R11]\]. Clinical applications of cocktails of targeting a specific phase of the cell cycle can be applied to modulate the subclonal evolution for prognosis, thereby guiding the timing of therapeutic intervention. The 38-cycle-related genes in the MammaPrint^®^ 70-gene panel, as confirmed by clinical specimens (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}), shed new light on subclonal evolution of common cancer treatment resistance, as certain cell-cycle stages, such G0, show resistance to treatment. This suggests that management of cell cycle stages can be therapeutic effective as it is tumor-subclone-specific, which is cell-cycle-dependent (Figure [3](#F3){ref-type="fig"}).

![Sequential perturbations of cell-cycle-phase-specific genes derived from single-cell transcriptomes of patient tumors are applied to treatment\
(**A**) After organizing single-cell transcriptomes by similarity into a sequential order (center-clustering), expression levels of various cell-cycle-phase-specific genes were plotted to visualize the sequential perturbation of individual genes during the cell cycle, a virtual time series. Expression levels were scaled from 0 (undetectable) to 1 (maximum expression). Cell cycle phases were defined and colored. As expected, G0/G1-specific genes had higher expression levels in the G0/G1 phase and an S-specific gene was mainly expressed within the S phase. G2/M-specific genes had high expression levels in G2/M phase and early G0/G1 phase. The sequential expression order suggests that mRNAs of many G2/M-specific genes are not degraded until early in G0/G1 phase after cell division. (**B**, **C**) Cancer subclones are defined by single-cell transcriptome-clustered cell cycle gene clustering (all cells in a subclone share and stay at one cell-cycle stage, which is used to guide treatment. The effective therapeutics drive the number of tumor subclones decrease while the number of tumor subclones at relapse increase.](oncotarget-09-33290-g003){#F3}

Such single-cell knowledge of categorizing distinct subpopulations of an organ may serve as a starting point to reconstruct the origins for the different subtypes of any organ-specific disease \[[@R12]\]. Single-cell identity may serve as a resource to map out the defined changes occurring during disease onset, potential to improve methods of detection and treatment. Next generation sequencing technology enables single-cell mRNA sequencing (scRNAseq) to create a high-resolution "molecular census of recognition" that was previously unseen cellular differences \[[@R13]\]. Isolated from prostate tumor and associated cells, for example, Calcinotto and colleagues identified two IL-23-regulated proteins (STAT3 and RORγ) that support androgen-receptor-associated tumor growth \[[@R14]\] in myeloid-derived suppressor cells (MDSCs) (including monocytes and neutrophils) at an immature state \[[@R15]\]. From insights into this immature state, novel therapies of either antibody (blocks IL-23) or enzalutamide (androgen-receptor inhibitor) were employed to shrink the tumors \[[@R16]\].

To secure efficacy of cell cycle-based therapy, physicians need to track down the spatiotemporal changes of each cell within breast tissue at molecular, cellular and tissue levels. Technologies (next generation sequencing technology, single-cell mRNA sequencing for single-cell gene signatures, and positioning imaging system for biomarkers \[[@R17]\]) can capture the spatiotemporal information that defines the cell-by-cell origins of breast cancer, in its earliest phases that acquire genetic alterations, potential for early cancer detection, leading to cancer prevention, slowing cancer progression or early management for co-survival with cancer \[[@R11]\], before it turns into a life-threatening cancer burden \[[@R18]\]. Such non-invasive imaging-based analysis of spatiotemporal gene-expression patterns \[[@R17]\] in single cells may shed new light onto the developmental processes that lead to "wait-and-watch" approaches \[[@R18]\], by defining "therapeutic windows" \[[@R19]\], with multiple check points of the full spectrum of cellular diversity that exists in the human body, in cancer initiation, progression and metastasis.

Cell cycle gene regulation plays a critical role not only in repair after tissue injury (e.g., stem cell-mediated regeneration), but also in cancer surveillance, and more recently has been employed as a tool in immunotherapy-based "wait-and-watch" approaches to cancer \[[@R18], [@R20]\]. Cell cycle gene regulation is tightly regulated by essential kinases such as members of the CDK family and their effectors. Monitoring cell cycle activity---including phenotyping immune cell and cancer stem cell subsets, tracking cell proliferation, and measuring cytokine production---can provide insights into the overall status of cancer in patients, and identify those cell populations which manage to survive cancer treatments. However, conventional gene expression profiling, which relies on population averaging of millions of heterogenous cells (malignant vs. normal cells), cannot realistically be expected to detect fine perturbations in gene expression that are precisely regulated on both temporal and spatial scales. Consequently, expression perturbations of many cell-cycle-related genes may remain masked in crude cell lysate analysis. The expression patterns of these cell-cycle genes as predicted by this algorithm remain to be validated in clinical trials for prognosis of other types of cancers.

Conclusion: With single-cell transcriptome analysis, we reveal that the previously unknown predictive power of MammaPrint^®^ signature panel arises from the cell cycle genes it profiles, and that the expression patterns of these cell cycle genes can be used for prognosis of other types of cancers.

MATERIALS AND METHODS {#s4}
=====================

Cell culture and single-cell cDNA synthesis {#s4_1}
-------------------------------------------

H9 human embryonic stem cells (WA09, WiCell Research Institute, Inc.) were maintained with a feeder-free protocol as previously described \[[@R21], [@R22]\]. HeLa F. (RIKEN Cell Bank RCB2812) cells (Fucci cells) \[[@R23]\] were grown under standard conditions and cultured in Advanced DMEM (Invitrogen, Carlsbad, California), 1% Fetal Bovine Serum (HyClone, South Logan, Utah) and 0.5% penicillin-streptomycin (Invitrogen, Carlsbad, California). Cells were trypsinized using TrypLE (GIBCO) and resuspended in 1X phosphate-based buffer (PBS). Single-cell encapsulation was performed through hydrodynamic flow controlled by syringe pumps connected to a custom-fabricated microfluidic device as described previously \[[@R24]\]. The single-cell encapsulation, cDNA synthesis and amplifications in a nanoliter scale were carried out as previously reported \[[@R25], [@R26]\] Briefly, single cells were encapsulated into 600 pico-liter droplets with T-junction microfluidic devices or laser cavitation devices \[[@R27]\]. These droplets then were manipulated into 10 nano-liter reactors for reverse transcription reaction and diluted to 10 μl. The resulting products were then stored at −20°C until they were used for quantitative PCR or microarray gene expression profiling (Illumina). Samples were prepared for PCR amplification and subsequent microarray analysis by adding preamplification master mix (Illumina, San Diego, CA) as described previously \[[@R25]\]. For comparison, a Single-Cell Preamplification Kit (Life-Technologies, CA) was also used for cDNA synthesis and subsequently for qPCR verification.

RNA-seq analysis {#s4_2}
----------------

For RNA-seq samples, trimmed reads were mapped onto human genome hg38 using Tophat 2.0.8 as implemented in Flow with default settings, using Gencode 20 annotation ([www.gencodegenes.org](http://www.gencodegenes.org)) as guidance. Gencode 20 annotation was used to quantify aligned reads to genes/transcripts using the Partek E/M method. \[[@R28]\] Read counts per gene in all samples were normalized using Upper Quartile normalization \[[@R29]\] and analyzed for differential expression using Partek\'s Gene Specific Analysis method (genes with less than 10 reads in any sample were excluded). To generate a list of significantly differentially expressed genes among different tissues of the same patient, a cutoff of FDR adjusted *p* \< 0.05 (Poisson regression) and fold change \>\|2\| was applied.

Gene expression normalization and QC {#s4_3}
------------------------------------

Illumina gene expression data from each sample was processed and normalized independently of the other tissue/sample types. Analyses were restricted to genes significantly expressed in all single HeLa cells and lysates at a nominal *p*-value of 0.01, yielding 2,181 significant expression features out of 29,377 annotated probes on the array. For assessing agreement between single-cell data and lysate data, both were processed using a log 2 transformation followed by quantile normalization. To maximize the signal-to-noise ratio for fine mapping of single cells to the cell cycle, a more comprehensive approach was taken. The Lumi R package \[[@R30]\] was used to employ a variance-stabilizing transformation \[[@R31]\] that utilizes technical replicates on the array followed by Robust Spline Normalization. Extreme outliers across single cells were identified on a probe-by-probe basis and the values were set to 'missing' if they were more extreme than three interquartile ranges away from the first or third quartiles. However, no more than one outlier exceeded this criterion per probe. Missing data were then inputted using a nearest-neighbor averaging method.

Statistical analysis {#s4_4}
--------------------

In cells that are approximately homogeneous with respect to factors other than their cell cycle stages, expression of cell cycle-related genes were used to determine the position in the cell cycle of each cell in relation to others. That is, similarity between cells in expression data was used to reflect similarity in cell cycle stage. We included in this analysis not only expressed genes (as described above), but also genes for which existing literature provided us with some evidence of their involvement in the cell cycle. Specifically, the inclusion criteria required that genes be classified in the GO category *cell cycle process* (GO:0022402). Among the many approaches that have been applied to clustering genes based on microarray expression patterns, Ray *et al*. \[[@R32]\] applied a traveling salesman problem (TSP) solver called Concorde \[[@R33]\] to obtain a one-dimensional ordering of genes within clusters. We used Concorde to estimate the shortest Hamiltonian path (a variation of the TSP where the path does not end at the starting position) based on Euclidean distance through the single cells (rather than genes). This approach required the construction of an adjacency matrix for single cells, which was generated using a network-based approach usually applied to the identification of co-expressed modules of genes \[[@R34]\].

The cell cycle status of individual cells forms a perturbation map, i.e., a diagram of how expression of a gene is perturbed as a cell passes through the cell cycle. This perturbation map was used with the Self-Organizing Maps (SOM) \[[@R35]\] approach to identify clusters of genes with the same perturbation signature. Genes with perturbation patterns similar to known cell cycle genes were inferred to be new candidate cell cycle genes.

Oncogene profiling database {#s4_5}
---------------------------

Multiple cancer profiling databases were used for cancer profile analyses, including Cancer Program Data Resources \| Cancer Program Resource Gateway, ONCOMINE (Cancer Microarray Database and Integrated Data), Cancer RNA-Seq Nexus (database of phenotype-specific genome-wide transcriptome profiling of cancerous and normal tissue samples), Cancer Gene Expression Database (CGED) (database for gene expression profiling with accompanying clinical information of human cancer), Genomics of Drug Sensitivity in Cancer, Cancer atlas (The Human Protein Atlas), The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website (Sanger Institute), Genomic Profiling in Cancer Patients ([ClinicalTrials.gov](http://ClinicalTrials.gov)), The Cancer Genome Atlas (TCGA), and International Cancer Genome Consortium. The relevant biomarkers were used to align with the single cell transcriptomes.
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